{"nctId":"NCT04558918","briefTitle":"Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment","startDateStruct":{"date":"2021-01-25","type":"ACTUAL"},"conditions":["Paroxysmal Nocturnal Hemoglobinuria (PNH)"],"count":97,"armGroups":[{"label":"LNP023 200mg b.i.d.","type":"EXPERIMENTAL","interventionNames":["Drug: LNP023"]},{"label":"Anti-C5 antibody","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Eculizumab","Drug: Ravulizumab"]}],"interventions":[{"name":"LNP023","otherNames":["iptacopan"]},{"name":"Eculizumab","otherNames":[]},{"name":"Ravulizumab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female participants ≥ 18 years of age with a diagnosis of PNH confirmed by high-sensitivity flow cytometry with clone size ≥ 10%\n* Stable regimen of anti-C5 antibody treatment (either eculizumab or ravulizumab) for at least 6 months prior to randomization\n* Mean hemoglobin level \\<10 g/dL\n* Vaccination against Neisseria meningitidis infection is required prior to the start of treatment.\n* If not received previously, vaccination against Streptococcus pneumoniae and Haemophilus influenzae infections should be given\n\nExclusion Criteria:\n\n* Participants on a stable eculizumab dose but with a dosing interval of 11 days or less or patients on stable ravulizumab dose but with a dosing interval of less than 8 weeks.\n* Known or suspected hereditary complement deficiency at screening\n* History of hematopoietic stem cell transplantation\n* Patients with laboratory evidence of bone marrow failure (reticulocytes \\<100x10E9/L; platelets \\<30x10E9/L; neutrophils \\<500x10E6/L).\n* Active systemic bacterial, viral (incl. COVID-19), or fungal infection within 14 days prior to study drug administration\n* A history of recurrent invasive infections caused by encapsulated organisms, e.g. meningococcus or pneumococcus.\n* Major concurrent comorbidities including but not limited to severe kidney disease (e.g., eGFR \\< 30 mL/min/1.73 m2, dialysis), advanced cardiac disease (e.g., NYHA class IV), severe pulmonary disease (e.g., severe pulmonary hypertension (WHO class IV)), or hepatic disease (e.g., active hepatitis) that in the opinion of the investigator precludes participant's participation in the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Marginal Proportion (Expressed as Percentages) of Participants With Sustained Increase in Hemoglobin Levels From Baseline of ≥ 2 g/dL in the Absence of Red Blood Cell Transfusions","description":"Sustained increase in hemoglobin levels (responder) is defined as an increase from baseline in hemoglobin levels ≥ 2 g/dL on three out of four measurements taken at the visits occurring in last six weeks (between Day 126 and 168) of the randomized treatment period, without requiring red blood cell (RBC) transfusions between Day 14 and Day 168. Requiring RBC transfusions refers to any patient receiving transfusions or meeting protocol defined criteria (Hemoglobin level ≤ 9 g/dL with signs /and or symptoms of sufficient severity to warrant a transfusion or Hemoglobin of ≤ 7 g/dL, regardless of presence of clinical signs and/or symptoms).\n\nThe term 'marginal proportion' can be interpreted as the population average probability of being a responder for each treatment group. These values include adjustment for baseline covariates and missing data has also been taken into account.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.3","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Marginal Proportion (Expressed as Percentages) of Participants With Sustained Hemoglobin Levels of ≥ 12 g/dL in the Absence of Red Blood Cell Transfusions","description":"Sustained hemoglobin levels (responder) is defined as hemoglobin levels ≥ 12 g/dL on three out of four measurements taken at the visits occurring in last six weeks (between Day 126 and 168) of the randomized treatment period, without requiring red blood cell (RBC) transfusions between Day 14 and Day 168. Requiring RBC transfusions refers to any patient receiving transfusions or meeting protocol defined criteria (Hemoglobin level ≤ 9 g/dL with signs /and or symptoms of sufficient severity to warrant a transfusion or Hemoglobin of ≤ 7 g/dL, regardless of presence of clinical signs and/or symptoms).\n\nThe term 'marginal proportion' can be interpreted as the population average probability of being a responder for each treatment group. These values include adjustment for baseline covariates and missing data has also been taken into account.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.8","spread":null},{"groupId":"OG001","value":"1.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Patients Meeting Hematological Response Criterion After the Start of LNP023 Treatment","description":"Patients with hematological response are those with ≥ 2g/dL increase in hemoglobin from baseline regardless of transfusions and patients with Hb ≥ 12g/dL regardless of transfusions.\n\nPatients in the LNP023-LNP023 group received iptacopan from Day 1 to Day 336 (48 weeks) while patients in the anti-C5 antibody-LNP023 group received iptacopan from Day 169 to Day 336 (treatment extension period - 24 weeks).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.4","spread":null},{"groupId":"OG001","value":"72.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.8","spread":null},{"groupId":"OG001","value":"58.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Patients Not Requiring RBC Transfusions After the Start of LNP023 Treatment","description":"Requiring RBC transfusions refers to any patient receiving transfusions or meeting protocol defined criteria (Hemoglobin level ≤ 9 g/dL with signs /and or symptoms of sufficient severity to warrant a transfusion or Hemoglobin of ≤ 7 g/dL, regardless of presence of clinical signs and/or symptoms).\n\nPatients randomized to anti-C5 treatment switched to LNP023 (iptacopan) on Day 169 and were treated until Day 336 (treatment extension period).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin at Visit Day 336","description":"Patients randomized to anti-C5 treatment switched to LNP023 (iptacopan) on Day 169 and were treated until Day 336 (treatment extension period).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.35","spread":null},{"groupId":"OG001","value":"3.36","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in FACIT-Fatigue Questionnaire at Day 336","description":"The FACIT-Fatigue is a 13-item questionnaire with support for its validity and reliability in PNH that assesses patient self-reported fatigue and its impact on daily activities and function. All FACIT scales are scored so that a high score is better. As each of the 13 items of the FACIT-F Scale ranges from 0-4, the range of possible scores is 0-52, with 0 being the worst possible score and 52 the best.\n\nPatients randomized to anti-C5 treatment switched to LNP023 (iptacopan) on Day 169 and were treated until Day 336 (treatment extension period).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.80","spread":null},{"groupId":"OG001","value":"10.96","spread":null}]}]}]},{"type":"SECONDARY","title":"Marginal Proportion (Expressed as Percentages) of Participants Who Remain Free From Transfusions","description":"Marginal proportion (expressed as percentages) of participants who did not require transfusions between Day 14 and Day 168. Requiring red blood cell transfusions refers to any patient receiving transfusions or meeting protocol defined criteria (Hemoglobin level ≤ 9 g/dL with signs /and or symptoms of sufficient severity to warrant a transfusion or Hemoglobin of ≤ 7 g/dL, regardless of presence of clinical signs and/or symptoms). The term 'marginal proportion' can be interpreted as the population average probability of being a responder for each treatment group. These values include adjustment for baseline covariates and missing data has also been taken into account.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.8","spread":null},{"groupId":"OG001","value":"25.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Hemoglobin Between Day 126 and 168","description":"Change from baseline in hemoglobin levels as mean of visits between Day 126 and Day 168.\n\nFor this analysis, in order to factor out the effect of transfusions, if a patient had a transfusion during the randomized treatment period, then the hemoglobin values 30 days following the transfusion were excluded and hemoglobin data were imputed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.60","spread":null},{"groupId":"OG001","value":"-0.06","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in FACIT-Fatigue Questionnaire in the Randomized Treatment Period","description":"The FACIT-Fatigue is a 13-item questionnaire with support for its validity and reliability in PNH that assesses patient self-reported fatigue and its impact on daily activities and function. All FACIT scales are scored so that a high score is better. As each of the 13 items of the FACIT-F Scale ranges from 0-4, the range of possible scores is 0-52, with 0 being the worst possible score and 52 the best.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.59","spread":null},{"groupId":"OG001","value":"0.31","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Absolute Reticulocyte Count in the Randomized Treatment Period","description":"Change from baseline in absolute reticulocyte count as mean of visits between Day 126 and Day 168","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-115.81","spread":null},{"groupId":"OG001","value":"0.34","spread":null}]}]}]},{"type":"SECONDARY","title":"Ratio to Baseline in Log-transformed LDH in the Randomized Treatment Period","description":"Average of the Lactate dehydrogenase (LDH) log transformed ratio to baseline in each treatment estimated between Day 126 and Day 168.The log transformation used refers to the natural log (base of e).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.96","spread":null},{"groupId":"OG001","value":"0.98","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Annualized Clinical BTH Rate in the Randomized Treatment Period","description":"Adjusted annualized rate of clinical breakthrough hemolysis (BTH) events are from negative binomial model.\n\nA patient with multiple occurrences of an event under one treatment is counted only once for that treatment.\n\nThe breakthrough is defined clinical if either there is a decrease in hemoglobin levels equal to or more than 2 g/dL (compared to the latest assessment, or within 15 days) or if patients present signs or symptoms of gross hemoglobinuria, painful crisis, dysphagia or any other significant clinical PNH-related signs \\& symptoms, in presence of laboratory evidence of intravascular hemolysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":null},{"groupId":"OG001","value":"0.67","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Annualized Major Adverse Vascular Events Rate in the Randomized Treatment Period","description":"Adjusted annualized Major Adverse Vascular Events (MAVEs incl. thrombosis) rate. A MAVE is defined as: acute peripheral vascular occlusion, amputation (non-traumatic; nondiabetic), cerebral arterial occlusion/cerebrovascular accident, cerebral venous occlusion, dermal thrombosis, gangrene (non-traumatic; nondiabetic), hepatic/portal vein thrombosis (Budd-Chiari syndrome), mesenteric/visceral arterial, thrombosis or infarction, mesenteric/visceral vein thrombosis or infarction, myocardial infarction, pulmonary embolus, renal arterial thrombosis, renal vein thrombosis, thrombophlebitis / deep vein thrombosis, transient ischemic attack, unstable angina or other.\n\nA patient with multiple occurrences of an event under one treatment is counted only once for that treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":null},{"groupId":"OG001","value":"0.00","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in Absolute Reticulocyte Count at Day 336","description":"Change from baseline in absolute reticulocyte count at visit Day 336. Patients randomized to anti-C5 antibody were switched to LNP023 (iptacopan) on Day 169 and were treated until Day 336 (treatment extension period).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-106.26","spread":null},{"groupId":"OG001","value":"-107.95","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Ratio to Baseline in Log-transformed LDH at Visit Day 336","description":"Average of the Lactate dehydrogenase (LDH) log transformed ratio to baseline at visit Day 336.The log transformation used refers to the natural log (base of e).\n\nPatients randomized to anti-C5 treatment switched to LNP023 (iptacopan) on Day 169 and were treated until Day 336 (treatment extension period).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.11","spread":null},{"groupId":"OG001","value":"0.99","spread":null}]}]}]},{"type":"PRIMARY","title":"Adjusted Annualized Clinical BTH Rate After the Start of LNP023 Treatment","description":"This endpoint is considering clinical BTH events after the start of LNP023 treatment. Therefore, results are presented in a single arm on LNP023 since it includes all patients in the Combined Full analysis set.\n\nAdjusted annualized rate of clinical breakthrough hemolysis (BTH) events are from negative binomial model. A patient with multiple occurrences of an event under one treatment is counted only once for that treatment.The breakthrough is defined clinical if either there is a decrease in hemoglobin levels equal to or more than 2 g/dL (compared to the latest assessment, or within 15 days) or if patients present signs or symptoms of gross hemoglobinuria, painful crisis, dysphagia or any other significant clinical PNH-related signs \\& symptoms, in presence of laboratory evidence of intravascular hemolysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":null}]}]}]},{"type":"PRIMARY","title":"Adjusted Annualized Major Adverse Vascular Events Rate After the Start of LNP023 Treatment","description":"This endpoint is considering clinical BTH events after the start of LNP023 treatment. Therefore, results are presented in a single arm on LNP023 since it includes all patients in the Combined Full analysis set.\n\nAdjusted annualized Major Adverse Vascular Events (MAVEs incl. thrombosis) rate. A MAVE is defined as: acute peripheral vascular occlusion, amputation (non-traumatic; nondiabetic), cerebral arterial occlusion/cerebrovascular accident, cerebral venous occlusion, dermal thrombosis, gangrene (non-traumatic; nondiabetic), hepatic/portal vein thrombosis (Budd-Chiari syndrome), mesenteric/visceral arterial, thrombosis or infarction, mesenteric/visceral vein thrombosis or infarction, myocardial infarction, pulmonary embolus, renal arterial thrombosis, renal vein thrombosis, thrombophlebitis / deep vein thrombosis, transient ischemic attack, unstable angina or other.\n\nA patient with multiple occurrences of an event under one treatment is counted only once for that treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":62},"commonTop":["COVID-19","Headache","Diarrhoea","Nasopharyngitis","Nausea"]}}}